Supernus Pharmaceuticals, Inc. (SUPN) Worth Watching: Stock Surges 13.2%

Zacks Equity Research
December 26, 2013


Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares rise over 13% on the day. This jump can be attributable to solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock is now up 16.9% in the past one-month time frame.

Over the last 30 days, Supernus Pharmaceuticals did not witness any estimate revision and the Zacks Consensus Estimate has remained unchanged. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.

Supernus Pharmaceuticals currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the healthcare industry include Heska Corporation (HSKY), Questcor Pharmaceuticals, Inc. (QCOR) and Forest Laboratories Inc. (FRX) with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>







SUPERNUS PHARMACEUTICALS INC (SUPN): Free Stock Analysis Report

FOREST LABS INC (FRX): Free Stock Analysis Report

HESKA CORP (HSKA): Free Stock Analysis Report

QUESTCOR PHARMACEUTICALS INC (QCOR): Free Stock Analysis Report


Zacks Investment Research